Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy

Paul W. X. Foley, Berthold Stegemann, Kelvin Ng, Selvakumar Ramachandran, Anthony Proudler, Michael Frenneaux, Leong L. Ng, Francisco Leyva

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The aim of this study was to determine whether growth differentiation factor-15 (GDF-15) predicts mortality and morbidity after cardiac resynchronization therapy (CRT). Growth differentiation factor-15, a transforming growth factor-beta-related cytokine which is up-regulated in cardiomyocytes via multiple stress pathways, predicts mortality in patients with heart failure treated pharmacologically.

Growth differentiation factor-15 was measured before and 360 days (median) after implantation in 158 patients with heart failure [age 68 +/- 11 years (mean +/- SD), left ventricular ejection fraction (LVEF) 23.1 +/- 9.8%, New York Class Association (NYHA) class III (n = 117) or IV (n = 41), and QRS 153.9 +/- 28.2 ms] undergoing CRT and followed up for a maximum of 5.4 years for events. In a stepwise Cox proportional hazards model with bootstrapping, adopting log GDF-15, log NT pro-BNP, LVEF, and NYHA class as independent variables, only log GDF-15 [hazard ratio (HR), 3.76; P = 0.0049] and log NT pro-BNP (HR, 2.12; P = 0.0171) remained in the final model. In the latter, the bias-corrected slope was 0.85, the optimism (O) was -0.06, and the c-statistic was 0.74, indicating excellent internal validity. In univariate analyses, log GDF-15 [HR, 5.31; 95% confidence interval (CI), 2.31-11.9; likelihood ratio (LR) chi(2) = 14.6; P < 0.0001], NT pro-BNP (HR, 2.79; 95% CI, 1.55-5.26; LR chi(2) = 10.4; P = 0.0004), and the combination of both biomarkers (HR, 7.03; 95% CI, 2.91-17.5; LR chi(2) = 19.1; P < 0.0001) emerged as significant predictors. The biomarker combination was associated with the highest LR chi(2) for all endpoints.

Pre-implant GDF-15 is a strong predictor of mortality and morbidity after CRT, independent of NT pro-BNP. The predictive value of these analytes is enhanced by combined measurement.

Original languageEnglish
Pages (from-to)2749-2757
Number of pages9
JournalEuropean Heart Journal
Volume30
Issue number22
DOIs
Publication statusPublished - Nov 2009

Keywords

  • growth differentiation factor-15
  • cardiac resynchronization therapy
  • heart failure
  • mortality
  • chronic heart-failure
  • acute coronary syndrome
  • factor-beta
  • prognostic utility
  • superfamily
  • survival
  • issues
  • member
  • model

Cite this

Foley, P. W. X., Stegemann, B., Ng, K., Ramachandran, S., Proudler, A., Frenneaux, M., ... Leyva, F. (2009). Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. European Heart Journal, 30(22), 2749-2757. https://doi.org/10.1093/eurheartj/ehp300

Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. / Foley, Paul W. X.; Stegemann, Berthold; Ng, Kelvin; Ramachandran, Selvakumar; Proudler, Anthony; Frenneaux, Michael; Ng, Leong L.; Leyva, Francisco.

In: European Heart Journal, Vol. 30, No. 22, 11.2009, p. 2749-2757.

Research output: Contribution to journalArticle

Foley, PWX, Stegemann, B, Ng, K, Ramachandran, S, Proudler, A, Frenneaux, M, Ng, LL & Leyva, F 2009, 'Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy', European Heart Journal, vol. 30, no. 22, pp. 2749-2757. https://doi.org/10.1093/eurheartj/ehp300
Foley, Paul W. X. ; Stegemann, Berthold ; Ng, Kelvin ; Ramachandran, Selvakumar ; Proudler, Anthony ; Frenneaux, Michael ; Ng, Leong L. ; Leyva, Francisco. / Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. In: European Heart Journal. 2009 ; Vol. 30, No. 22. pp. 2749-2757.
@article{faa73acfb0c54546a1fd00f5b742c459,
title = "Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy",
abstract = "The aim of this study was to determine whether growth differentiation factor-15 (GDF-15) predicts mortality and morbidity after cardiac resynchronization therapy (CRT). Growth differentiation factor-15, a transforming growth factor-beta-related cytokine which is up-regulated in cardiomyocytes via multiple stress pathways, predicts mortality in patients with heart failure treated pharmacologically.Growth differentiation factor-15 was measured before and 360 days (median) after implantation in 158 patients with heart failure [age 68 +/- 11 years (mean +/- SD), left ventricular ejection fraction (LVEF) 23.1 +/- 9.8{\%}, New York Class Association (NYHA) class III (n = 117) or IV (n = 41), and QRS 153.9 +/- 28.2 ms] undergoing CRT and followed up for a maximum of 5.4 years for events. In a stepwise Cox proportional hazards model with bootstrapping, adopting log GDF-15, log NT pro-BNP, LVEF, and NYHA class as independent variables, only log GDF-15 [hazard ratio (HR), 3.76; P = 0.0049] and log NT pro-BNP (HR, 2.12; P = 0.0171) remained in the final model. In the latter, the bias-corrected slope was 0.85, the optimism (O) was -0.06, and the c-statistic was 0.74, indicating excellent internal validity. In univariate analyses, log GDF-15 [HR, 5.31; 95{\%} confidence interval (CI), 2.31-11.9; likelihood ratio (LR) chi(2) = 14.6; P < 0.0001], NT pro-BNP (HR, 2.79; 95{\%} CI, 1.55-5.26; LR chi(2) = 10.4; P = 0.0004), and the combination of both biomarkers (HR, 7.03; 95{\%} CI, 2.91-17.5; LR chi(2) = 19.1; P < 0.0001) emerged as significant predictors. The biomarker combination was associated with the highest LR chi(2) for all endpoints.Pre-implant GDF-15 is a strong predictor of mortality and morbidity after CRT, independent of NT pro-BNP. The predictive value of these analytes is enhanced by combined measurement.",
keywords = "growth differentiation factor-15, cardiac resynchronization therapy, heart failure, mortality, chronic heart-failure, acute coronary syndrome, factor-beta, prognostic utility, superfamily, survival, issues, member, model",
author = "Foley, {Paul W. X.} and Berthold Stegemann and Kelvin Ng and Selvakumar Ramachandran and Anthony Proudler and Michael Frenneaux and Ng, {Leong L.} and Francisco Leyva",
year = "2009",
month = "11",
doi = "10.1093/eurheartj/ehp300",
language = "English",
volume = "30",
pages = "2749--2757",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "OXFORD UNIV PRESS",
number = "22",

}

TY - JOUR

T1 - Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy

AU - Foley, Paul W. X.

AU - Stegemann, Berthold

AU - Ng, Kelvin

AU - Ramachandran, Selvakumar

AU - Proudler, Anthony

AU - Frenneaux, Michael

AU - Ng, Leong L.

AU - Leyva, Francisco

PY - 2009/11

Y1 - 2009/11

N2 - The aim of this study was to determine whether growth differentiation factor-15 (GDF-15) predicts mortality and morbidity after cardiac resynchronization therapy (CRT). Growth differentiation factor-15, a transforming growth factor-beta-related cytokine which is up-regulated in cardiomyocytes via multiple stress pathways, predicts mortality in patients with heart failure treated pharmacologically.Growth differentiation factor-15 was measured before and 360 days (median) after implantation in 158 patients with heart failure [age 68 +/- 11 years (mean +/- SD), left ventricular ejection fraction (LVEF) 23.1 +/- 9.8%, New York Class Association (NYHA) class III (n = 117) or IV (n = 41), and QRS 153.9 +/- 28.2 ms] undergoing CRT and followed up for a maximum of 5.4 years for events. In a stepwise Cox proportional hazards model with bootstrapping, adopting log GDF-15, log NT pro-BNP, LVEF, and NYHA class as independent variables, only log GDF-15 [hazard ratio (HR), 3.76; P = 0.0049] and log NT pro-BNP (HR, 2.12; P = 0.0171) remained in the final model. In the latter, the bias-corrected slope was 0.85, the optimism (O) was -0.06, and the c-statistic was 0.74, indicating excellent internal validity. In univariate analyses, log GDF-15 [HR, 5.31; 95% confidence interval (CI), 2.31-11.9; likelihood ratio (LR) chi(2) = 14.6; P < 0.0001], NT pro-BNP (HR, 2.79; 95% CI, 1.55-5.26; LR chi(2) = 10.4; P = 0.0004), and the combination of both biomarkers (HR, 7.03; 95% CI, 2.91-17.5; LR chi(2) = 19.1; P < 0.0001) emerged as significant predictors. The biomarker combination was associated with the highest LR chi(2) for all endpoints.Pre-implant GDF-15 is a strong predictor of mortality and morbidity after CRT, independent of NT pro-BNP. The predictive value of these analytes is enhanced by combined measurement.

AB - The aim of this study was to determine whether growth differentiation factor-15 (GDF-15) predicts mortality and morbidity after cardiac resynchronization therapy (CRT). Growth differentiation factor-15, a transforming growth factor-beta-related cytokine which is up-regulated in cardiomyocytes via multiple stress pathways, predicts mortality in patients with heart failure treated pharmacologically.Growth differentiation factor-15 was measured before and 360 days (median) after implantation in 158 patients with heart failure [age 68 +/- 11 years (mean +/- SD), left ventricular ejection fraction (LVEF) 23.1 +/- 9.8%, New York Class Association (NYHA) class III (n = 117) or IV (n = 41), and QRS 153.9 +/- 28.2 ms] undergoing CRT and followed up for a maximum of 5.4 years for events. In a stepwise Cox proportional hazards model with bootstrapping, adopting log GDF-15, log NT pro-BNP, LVEF, and NYHA class as independent variables, only log GDF-15 [hazard ratio (HR), 3.76; P = 0.0049] and log NT pro-BNP (HR, 2.12; P = 0.0171) remained in the final model. In the latter, the bias-corrected slope was 0.85, the optimism (O) was -0.06, and the c-statistic was 0.74, indicating excellent internal validity. In univariate analyses, log GDF-15 [HR, 5.31; 95% confidence interval (CI), 2.31-11.9; likelihood ratio (LR) chi(2) = 14.6; P < 0.0001], NT pro-BNP (HR, 2.79; 95% CI, 1.55-5.26; LR chi(2) = 10.4; P = 0.0004), and the combination of both biomarkers (HR, 7.03; 95% CI, 2.91-17.5; LR chi(2) = 19.1; P < 0.0001) emerged as significant predictors. The biomarker combination was associated with the highest LR chi(2) for all endpoints.Pre-implant GDF-15 is a strong predictor of mortality and morbidity after CRT, independent of NT pro-BNP. The predictive value of these analytes is enhanced by combined measurement.

KW - growth differentiation factor-15

KW - cardiac resynchronization therapy

KW - heart failure

KW - mortality

KW - chronic heart-failure

KW - acute coronary syndrome

KW - factor-beta

KW - prognostic utility

KW - superfamily

KW - survival

KW - issues

KW - member

KW - model

U2 - 10.1093/eurheartj/ehp300

DO - 10.1093/eurheartj/ehp300

M3 - Article

VL - 30

SP - 2749

EP - 2757

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 22

ER -